DE2949491C2 - - Google Patents
Info
- Publication number
- DE2949491C2 DE2949491C2 DE2949491A DE2949491A DE2949491C2 DE 2949491 C2 DE2949491 C2 DE 2949491C2 DE 2949491 A DE2949491 A DE 2949491A DE 2949491 A DE2949491 A DE 2949491A DE 2949491 C2 DE2949491 C2 DE 2949491C2
- Authority
- DE
- Germany
- Prior art keywords
- formula
- group
- compound
- compounds according
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims description 25
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical class C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 230000017531 blood circulation Effects 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960001597 nifedipine Drugs 0.000 description 3
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 230000002213 calciumantagonistic effect Effects 0.000 description 2
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- YBBRQAXNTWMMFZ-UHFFFAOYSA-N 2,1,3-benzoxadiazole-4-carbaldehyde Chemical compound O=CC1=CC=CC2=NON=C12 YBBRQAXNTWMMFZ-UHFFFAOYSA-N 0.000 description 1
- ZYXNLVMBIHVDRH-UHFFFAOYSA-N 2-Methylpropyl 3-oxobutanoate Chemical compound CC(C)COC(=O)CC(C)=O ZYXNLVMBIHVDRH-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 230000003257 anti-anginal effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- -1 methyl β- aminocrotonic acid Chemical compound 0.000 description 1
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000004895 regional blood flow Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH548480A CH654836A5 (en) | 1979-12-08 | 1980-07-17 | Heterocyclic organic compounds and therapeutic agents containing them |
| PH24383A PH19536A (en) | 1977-06-20 | 1980-08-01 | Benzoxadiazoles and benzothiadiazoles and pharmaceutical composition containing them |
| MX9203580A MX9203580A (es) | 1979-12-08 | 1992-06-26 | 1,4-dihidropiridinas y composiciones farmaceuticas que las contienen. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1283578A CH639659A5 (de) | 1978-12-18 | 1978-12-18 | Neue 1,4-dihydropyridinderivate, deren herstellung und verwendung. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2949491A1 DE2949491A1 (de) | 1980-06-26 |
| DE2949491C2 true DE2949491C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1988-10-27 |
Family
ID=4386824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19792949491 Granted DE2949491A1 (de) | 1977-06-20 | 1979-12-08 | 1,4-dihydropyridine, ihre herstellung und verwendung |
Country Status (18)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3317691A1 (de) * | 1982-03-22 | 1984-11-22 | Bristol-Myers Co., New York, N.Y. | Cyclische dihydropyridylimidatester, verfahren zu ihrer herstellung und pharmazeutische mittel |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3022030A1 (de) * | 1980-06-12 | 1981-12-17 | Bayer Ag, 5090 Leverkusen | 4-thiazol- bzw. 4-imidazol-substituierte, 1,4-dihydropyridine, verfahren zu deren herstellung sowie diese enthaltende arzneimittel |
| CH655658B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1980-09-18 | 1986-05-15 | ||
| DE3269219D1 (en) * | 1981-11-17 | 1986-03-27 | Fisons Plc | Dihydropyridines, methods for their production and their formulation and use as pharmaceuticals |
| ZA83959B (en) * | 1982-03-10 | 1984-09-26 | Sandoz Ltd | 1,4-dihydropyridine derivatives,their preparation and pharmaceutical compositions containing them |
| IL68975A (en) * | 1982-06-15 | 1987-01-30 | Sandoz Ag | 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydropyridine-3,5-dicarboxylic acid ester derivatives in optically active form,their preparation and pharmaceutical compositions containing them |
| FR2528431B1 (fr) * | 1982-06-15 | 1986-01-10 | Sandoz Sa | Nouveaux derives de la 1,4-dihydropyridine, leur preparation et leur utilisation comme medicaments |
| JPS5978186A (ja) * | 1982-10-27 | 1984-05-04 | Yoshitomi Pharmaceut Ind Ltd | １，４−ジヒドロピリジン−３，５−ジカルボン酸エステル誘導体 |
| US4794111A (en) * | 1984-05-23 | 1988-12-27 | Bayer Aktiengesellschaft | Dihydropyridine preparations containing β-blockers |
| HU198844B (en) * | 1984-06-14 | 1989-12-28 | Sandoz Ag | Process for producing new galenic pharmaceutical composition ensuring retarded release of active ingredient |
| US5260321A (en) * | 1984-11-12 | 1993-11-09 | Sandoz Ltd. | Use of 1,4-dihydropyridine derivatives and combinations thereof with calcitonins |
| HU197201B (en) * | 1985-10-01 | 1989-03-28 | Sandoz Ag | Process for producing oral pharmaceutical compositions of controlled solubility of the active components |
| DE3542794A1 (de) * | 1985-12-04 | 1987-06-11 | Bayer Ag | Antihypertensives kombinationspraeparat |
| GB8626217D0 (en) * | 1986-11-03 | 1986-12-03 | Sandoz Ltd | Pharmaceutical compositions |
| US4816263A (en) * | 1987-10-02 | 1989-03-28 | Alza Corporation | Dosage form for treating cardiovascular diseases comprising isradipine |
| KR940003492B1 (ko) * | 1988-10-27 | 1994-04-23 | 주식회사 유한양행 | 1,4-디하이드로피리딘유도체 및 그의 제조방법 |
| DE4222770A1 (de) * | 1992-07-10 | 1994-01-13 | Bayer Ag | Lichtaktivierbare 1-(2-Nitrobenzyl)-substituierte 1,4-Dihydropyridine |
| EP2316469A1 (en) | 2002-02-22 | 2011-05-04 | Shire LLC | Delivery system and methods for protecting and administering dextroamphetamine |
| WO2005023787A1 (en) * | 2003-09-10 | 2005-03-17 | Shasun Chemicals And Drugs Limited | Process for the manufacture of 2,1,3-benzoxadiazole-4-carboxaldehyde |
| CN103613584B (zh) * | 2013-11-27 | 2016-04-27 | 沈阳药科大学 | 一种伊拉地平合成产物后处理的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1670824C3 (de) * | 1967-03-20 | 1978-08-03 | Bayer Ag, 5090 Leverkusen | 1,4-Dihydropyridin-33-dicarbonsäurealkylester |
| FR2320750A1 (fr) * | 1975-08-12 | 1977-03-11 | Hexachimie | Dihydro-1,4 pyridines et leur application therapeutique |
| DE2616991A1 (de) * | 1976-04-17 | 1977-10-27 | Bayer Ag | Heterocyclisch-substituierte schwefelhaltige dihydropyridine, mehrere verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
| JPS5373327A (en) * | 1976-12-13 | 1978-06-29 | Matsushita Electric Ind Co Ltd | Power source system |
| FI64938C (fi) * | 1977-06-20 | 1984-02-10 | Sandoz Ag | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara bensoxa- och bensotiadiazolyl-1,4-dihydropyridinderivat |
-
1978
- 1978-12-18 CH CH1283578A patent/CH639659A5/de not_active IP Right Cessation
-
1979
- 1979-12-08 DE DE19792949491 patent/DE2949491A1/de active Granted
- 1979-12-11 SE SE7910188A patent/SE445219B/sv not_active IP Right Cessation
- 1979-12-13 BE BE1/9643A patent/BE880591A/fr not_active IP Right Cessation
- 1979-12-14 IT IT51095/79A patent/IT1164097B/it active Protection Beyond IP Right Term
- 1979-12-14 GB GB7943113A patent/GB2037766B/en not_active Expired
- 1979-12-14 CY CY1321A patent/CY1321A/en unknown
- 1979-12-14 GB GB08215988A patent/GB2103203B/en not_active Expired
- 1979-12-14 NL NL7909024A patent/NL193066C/nl not_active IP Right Cessation
- 1979-12-17 FR FR7930829A patent/FR2444681A1/fr active Granted
- 1979-12-17 NZ NZ192422A patent/NZ192422A/xx unknown
- 1979-12-17 AU AU53896/79A patent/AU536055B2/en not_active Expired
- 1979-12-17 IE IE2445/79A patent/IE49496B1/en not_active IP Right Cessation
- 1979-12-17 JP JP16396579A patent/JPS5583783A/ja active Granted
- 1979-12-18 ZA ZA00796842A patent/ZA796842B/xx unknown
-
1985
- 1985-12-20 SG SG975/85A patent/SG97585G/en unknown
- 1985-12-30 MY MY130/85A patent/MY8500130A/xx unknown
-
1986
- 1986-01-08 KE KE3593A patent/KE3593A/xx unknown
- 1986-03-06 HK HK160/86A patent/HK16086A/xx not_active IP Right Cessation
-
1999
- 1999-05-11 NL NL990014C patent/NL990014I1/nl unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3317691A1 (de) * | 1982-03-22 | 1984-11-22 | Bristol-Myers Co., New York, N.Y. | Cyclische dihydropyridylimidatester, verfahren zu ihrer herstellung und pharmazeutische mittel |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0369910B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1991-11-05 |
| NL193066C (nl) | 1998-09-08 |
| FR2444681B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1982-10-29 |
| GB2103203A (en) | 1983-02-16 |
| MY8500130A (en) | 1985-12-31 |
| KE3593A (en) | 1986-02-07 |
| JPS5583783A (en) | 1980-06-24 |
| AU5389679A (en) | 1980-06-26 |
| ZA796842B (en) | 1981-07-29 |
| SE7910188L (sv) | 1980-06-19 |
| IT7951095A0 (it) | 1979-12-14 |
| GB2037766A (en) | 1980-07-16 |
| GB2037766B (en) | 1983-02-16 |
| CY1321A (en) | 1986-06-27 |
| NL193066B (nl) | 1998-05-06 |
| DE2949491A1 (de) | 1980-06-26 |
| SG97585G (en) | 1986-07-18 |
| CH639659A5 (de) | 1983-11-30 |
| AU536055B2 (en) | 1984-04-19 |
| SE445219B (sv) | 1986-06-09 |
| IT1164097B (it) | 1987-04-08 |
| HK16086A (en) | 1986-03-14 |
| NZ192422A (en) | 1982-09-14 |
| BE880591A (fr) | 1980-06-13 |
| NL7909024A (nl) | 1980-06-20 |
| FR2444681A1 (fr) | 1980-07-18 |
| GB2103203B (en) | 1983-06-08 |
| IE792445L (en) | 1980-06-18 |
| IE49496B1 (en) | 1985-10-16 |
| NL990014I1 (nl) | 1999-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2949491C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| EP0088276B1 (de) | Neue Verbindungen, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel | |
| DE2508181C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| EP0011706B1 (de) | Verfahren zur Herstellung von teilweise neuen 1,4-Dihydropyridin-3-carbonsäure-Derivaten (I), neue 1,4-Dihydropyridin-3-carbonsäure-Derivate (II) und die Verwendung der Derivate (I) und (II) zur Herstellung von 1,4-Dihydropyridin-3,5-dicarbonsäurediestern | |
| EP0088274A1 (de) | Neue 1,4-Dihydropyridine, Verfahren zu ihrer Herstellung und ihrer Verwendung in Arzneimitteln | |
| DD154014A5 (de) | Verfahren zur herstellung von optisch aktiven-1,4-dihydropyridinen | |
| DE2117571A1 (de) | Unsymmetrische 1,4-Dihydropyridincarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel I. Arfm: Farbenfabriken Bayer AG, 5090 Leverkusen | |
| EP0071819A1 (de) | Dihydropyridine mit positiv inotroper Wirkung, neue Verbindungen, ihre Verwendung in Arzneimitteln und Verfahren zu ihrer Herstellung | |
| EP0002208A1 (de) | Nitrosubstituierte 1,4-Dihydropyridine, diese enthaltende Arzneimittel sowie deren Herstellung | |
| DE2658183A1 (de) | In 2-position substituierte 1,4- dihydropyridin-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel | |
| DE2117572A1 (de) | Unsymmetrische 1,4-Dihydropyridine, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel II | |
| EP0103796A2 (de) | Neue Dihydropyrimidine, Verfahren zu ihrer Herstellung sowie ihre Verwendung in Arzneimitteln | |
| DE2407115A1 (de) | Neue 1,4-dihydropyridinderivate | |
| EP0009206B1 (de) | Fluorhaltige 1,4-Dihydropyridine, diese enthaltende Arzneimittel sowie Verfahren zu ihrer Herstellung | |
| CH664757A5 (de) | Pharmazeutisch nuetzliche dihydropyridinylcarbonsaeureamide und ester. | |
| EP0296316A1 (de) | 1,4-Dihydropyridin-Enantiomere | |
| CH622507A5 (en) | Process for the preparation of 1,4-dihydropyridines | |
| DE2210667A1 (de) | Kondensiert aromatisch substituierte 1,4-dihydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel | |
| EP0123112B1 (de) | Chromon- und thiochromonsubstituierte 1,4-Dihydropyridinderivate, mehrere Verfahren zu ihrer Herstellung sowie ihre Verwendung in Arzneimitteln | |
| EP0110259B1 (de) | 1,4-Dihydropyridinderivate, Verfahren zu ihrer Herstellung sowie ihre Verwendung in Arzneimitteln | |
| EP0010130A1 (de) | Sila-substituierte 1,4-Dihydropyridinderivate, Verfahren zu ihrer Herstellung, Arzneimittel und Verfahren zu deren Herstellung | |
| EP0039863A1 (de) | 1,4-Dihydropyridine mit unterschiedlichen Substituenten in 2- und 6-Position, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln | |
| DE3601397A1 (de) | Substituierte 1,4-dihydropyridin-3-carbonsaeurepiperazide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln | |
| EP0179386B1 (de) | 1,4-Dihydropyridin-hydroxyamine, Verfahren zu ihrer Herstellung sowie ihre Verwendung in Arzneimitteln | |
| DE3586817T2 (de) | 1,4-dihydropyridinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| V448 | Application of spc |
Free format text: PRODUCT NAME: ISRADIPIN; REGISTRATION NO/DATE: 17474.00.00, 17475.00.00, 22629.00.00; 19901029 Spc suppl protection certif: 193 75 087 Filing date: 19930630 |
|
| V457 | Spc granted |
Free format text: PRODUCT NAME: ISRADIPIN; REGISTRATION NO/DATE: 17474.00.00, 17475.00.00, 22629.00.00; 19901029 Spc suppl protection certif: 193 75 087 Filing date: 19930630 |
|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: NOVARTIS AG, BASEL, CH |
|
| 8328 | Change in the person/name/address of the agent |
Free format text: SPOTT WEINMILLER & PARTNER, 80336 MUENCHEN |
|
| V464 | Spc expired |
Free format text: PRODUCT NAME: ISRADIPIN; REGISTRATION NO/DATE: 17474.00.00, 17475.00.00, 22629.00.00; 19901029 Spc suppl protection certif: 193 75 087 Filing date: 19930630 |